FEATURE ARTICLES
What does 2026 ultimately hold for the industry? To explore that question, Lawrence Blatt, CEO of Aligos Therapeutics, sat down with me to share his perspective on the trends shaping the year ahead.
- What To Know About — And How To Apply For — FDA's PreCheck Pilot
- MES Is Still In The CD ROM Era But The Data Architecture Has Moved On
- The Rise Of The Autonomous Pharma Plant
- U.S. Pharma Tariffs And MFN In 2026: Manufacturing And Procurement Impact
- A Peek Into Novo Nordisk's Sustainable Facility Construction Mindset
- At Base Camp: Lilly's Manufacturing Capacity Journey
- The U.S. Has A New Vice To Squeeze Foreign Imports: Pharma Quality
PHARMA ONLINE WHITE PAPERS
-
![GettyImages-2174865889-scientists-laboratory-equipment-analysis]( "Make Your Production Sites Adaptable And More Efficient")
Make Your Production Sites Adaptable And More EfficientPharma faces mounting complexity and tighter margins, demanding agile, future-ready production. Discover how smart manufacturing enables faster adaptation and continuous therapy availability.
-
Epigenetics Application Guide10/2/2024
To fully understand biology and disease mechanisms, it is crucial to explore the role of epigenetic factors. Explore how epigenetic regulation works and methods to study these essential components.
-
GMP Compliance For Pharmaceuticals And Medical Devices3/14/2025
Good Manufacturing Practice (GMP) ensures products meet quality standards for their intended use, which covers all aspects of production. Explore how Ideagen supports GMP compliance across nine titles.
-
2024 Global Biopharma Sustainability Review9/3/2024
What steps is the biopharma industry taking to enhance sustainability? What challenges does biopharma encounter? And how can the entire industry draw lessons from the companies setting the standard?
-
Advancing QC Efficiency With SEC-MALS System And Empower Software7/31/2025
Discover how integration transforms lab workflows to enhance molecular characterization, streamline data management, and ensure compliance for superior data integrity and operational efficiency.
-
Leveraging 3 Distinct Resins To Provide Effective Impurity Removal For mAbs And Novel Antibody Derivatives11/3/2025
Due to the complexity of bispecifics, Fc-fusion proteins, and Fab fragments, their manufacturing poses added purification challenges and requires a robust toolkit of purification techniques.
PHARMA ONLINE APP NOTES & CASE STUDIES
- Comparing Process Development Approaches For Recombinant Proteins
- Liquids, Soft Foods As Vehicles For Enteric Coated Bead Drug Product
- Analytical Method Saves Dual-API Injectable Project From Stalling
- Overcoming Bispecific Antibody Purification Challenges
- Improve Speed To Market By Mitigating Vial And Stopper Incompatibility
NEWSLETTER ARCHIVE
- 03.03.26 -- Driving Fill-Finish Flexibility
- 03.03.26 -- The Rise Of The Autonomous Pharma Plant
- 02.26.26 -- At Base Camp: Lilly's Manufacturing Capacity Journey
- 02.26.26 -- STREAM Edition: Considerations For Single Use Disposables
- 02.25.26 -- Ready to design a scalable, cost optimized viral vector workflow?
INDUSTRY NEWS
-
![FDA Logo on phone screen-GettyImages-2208861549]( "Høeg In, Pazdur Out At The FDA")
Høeg In, Pazdur Out At The FDAWhat an eventful week it has been at the FDA, with Richard Pazdur, M.D., resigning after weeks in his position as director of Center for Drug Research and Evaluation (CDER), and his vacancy being quickly filled by acting director Tracy Beth Høeg, M.D.
-
![business peope negotiating-GettyImages-637902194]( "9 Drugs Granted Fast Track By FDA's Voucher Program")
9 Drugs Granted Fast Track By FDA's Voucher ProgramWith targets like pancreatic cancer, deafness, blindness, infertility and vaping addiction, these drugs were chosen due to an unmet need, addressing a public health crisis, boosting domestic manufacturing or increasing affordability.
-
![Pharmaceutical sorting machine, pills-GettyImages-1499814881]( "Leaders In The Excipient Market: Region And Type")
Leaders In The Excipient Market: Region And TypeThough North America led the market with a 38.32% market share of $3.15 billion in 2024, Asia Pacific is expected to have the fastest growth in the upcoming years.
-
![GettyImages-2189405678-GLP-1-obesity]( "Pfizer Strengthens Obesity Foothold With Metsera Acquisition")
Pfizer Strengthens Obesity Foothold With Metsera AcquisitionAfter discouraging efforts to bring two oral obesity drugs to market—danuglipron and lotiglipron—this acquisition launches Pfizer back into the obesity therapeutic game.
-
![weight loss, diabetes, insulin pen-GettyImages-2196049931]( "FDA Cracks Down On GLP-1 Imports")
FDA Cracks Down On GLP-1 ImportsGLP-1 bulk drug substances must be detained without physical examination (DWPE) unless they are on a list (Green List) of approved foreign GLP-1 manufacturers.
PHARMACEUTICAL ONLINE CONTENT COLLECTIONS
Explore how sterility assurance, including sterilization validation and environmental monitoring, is essential for controlling microbial contamination in mammalian cell production to ensure patient safety. Check out the latest e-book from Pharmaceutical Online.
More Content CollectionsSUPPLIER NEWS
-
Novartis Announces New Radioligand Therapy Manufacturing Facility In Denton, Texas2/26/2026
Novartis, a leading global innovative medicines company, today announced plans to establish a new 46,000-square-foot radioligand therapy (RLT) manufacturing site in Denton, Texas.
-
Quotient Sciences Extends Commercial Manufacturing Partnership For Ultra-Rare Disease Treatment2/26/2026
Quotient Sciences, a leading integrated CRDMO, announced an extended commercial supply partnership with Ipsen, a global biopharmaceutical company, to manufacture a treatment for Fibrodysplasia Ossificans Progressiva (FOP), an ultra-rare disease affecting fewer than 1,000 people worldwide.
-
Bora Pharmaceuticals And GSK Sign $250M Five Year Global Manufacturing Contract2/24/2026
This renewed collaboration reinforces the long-standing relationship between the two companies and expands the partnership, allowing GSK access to multiple sites within the Bora network, including its newest OSD site in Maple Grove, Minnesota.
-
AbbVie Announces $380 Million Investment With Two New Active Pharmaceutical Ingredient Manufacturing Facilities In Illinois2/24/2026
AbbVie (NYSE: ABBV) today announced a new $380 million investment to build two new active pharmaceutical ingredient (API) manufacturing facilities at its current North Chicago, Illinois, campus. These new state-of-the-art facilities will integrate advanced manufacturing technologies with artificial intelligence (AI) to support the production of AbbVie's next-generation neuroscience and obesity medications.
